Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 7/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | WDR5 | P61964 | 1/20 | 0.49 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17767754 | 0.81 | TGFBR1 (0.69) | TGFBR1MAPK14TGFBR2 | |
| SCHEMBL17767437 | 0.80 | TGFBR1 (0.68) | TGFBR1RAB9ANPC1POLBHPGD | |
| SCHEMBL7784464 | 0.79 | TGFBR1 (1.00) | TGFBR1ALDH1A1MAPK13MAPK12MAPK11 | |
| SCHEMBL17767695 | 0.78 | TGFBR1 (0.64) | TGFBR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL17767770 | 0.77 | TGFBR1 (0.63) | TGFBR1RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL7786549 | 0.76 | TGFBR1 (1.00) | TGFBR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL4569965 | 0.74 | RAB9A (0.68) | TGFBR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL29496952 | 0.74 | RAB9A (0.68) | TGFBR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL29496949 | 0.74 | RAB9A (0.68) | TGFBR1RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL17767722 | 0.74 | TGFBR1 (0.65) | TGFBR1ALDH1A1MEN1KMT2ATGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207531-B | Fused imidazole derivatives as TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | MIDCAP FINANCIAL TRUST | 2018-12-06 | — | — | US | disclosed |
| EP-3221318-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B&G PARTNERS, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2409708-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partners, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696693-B2 | Fused imidazole derivatives as TGF-beta inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885RAB9A 1984/4885MAPT 1420/4885 |
| US-20180346487-A1 | Fused Imidazole Derivatives as TGF-Beta Inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885RAB9A 1984/4885MAPT 1420/4885 |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | MUC1, NEU4, ALK | TGFBR1 1324/4885RAB9A 3453/4885MAPT 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.